Vimarsana
Biggest News Aggregation in the World

Page 2 - Test Assessment Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Test Assessment Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Test Assessment Program Today - Breaking & Trending Today

LumiraDx Limited (NASDAQ:LMDX) Q4 2022 Earnings Call Transcript - Vimarsana News

LumiraDx Limited (NASDAQ:LMDX) Q4 2022 Earnings Call Transcript

Operator: Good day and thank you for standing by. Welcome to the LumiraDx Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Investegate |LumiraDx Inc Announcements | LumiraDx Inc: LumiraDx Reports Fourth Quarter and Full Year 2022 Results - Vimarsana News

Investegate |LumiraDx Inc Announcements | LumiraDx Inc: LumiraDx Reports Fourth Quarter and Full Year 2022 Results

Investegate announcements from LumiraDx Inc, LumiraDx Reports Fourth Quarter and Full Year 2022 Results

LumiraDx Q4 revenues drop 65% on lower COVID-19 testing - Vimarsana News

LumiraDx Q4 revenues drop 65% on lower COVID-19 testing

The firm recorded an accounting impairment in Q4 for excess manufacturing and inventory related to the scale-up during peak COVID-19 testing demand and the decision to pause commercialization of its Amira COVID-19 test.

FDA Roundup: February 24, 2023 - Vimarsana News

FDA Roundup: February 24, 2023

/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA published the...

FDA authorizes Cepheid molecular test to detect monkeypox virus at the point of care - Vimarsana News

FDA authorizes Cepheid molecular test to detect monkeypox virus at the point of care

The Xpert Mpox test is a real-time polymerase chain reaction assay to detect Mpox virus DNA in lesion swab specimens from individuals suspected of monkeypox by their healthcare provider.